The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
Expert Rev Med Devices. 2013 Jul;10(4):453-9. doi: 10.1586/17434440.2013.811842.
The ethylene vinyl alcohol copolymer, Onyx® (ev3, Inc., MN, USA), is an embolic agent used in the management of arteriovenous malformations (AVMs) and was approved by the US FDA in 2005. Use of Onyx has resulted in higher curative rates compared with previous embolic agents such as N-butyl-2-cyanoacrylate. Onyx has several advantages over previous embolic agents. For instance, Onyx is a copolymer and does not adhere to catheters but solidifies slowly owing to the diffusion of its solvent dimethyl sulfoxide. This review focuses on different results obtained from the experience of different neurointerventionalists with an emphasis on the aim to cure. The studies presented are compared in terms of curative rates, morbidity and mortality. Ideas are presented for future treatment options for AVM rupture using nanotargeted therapy with the guide of specific markers highly expressed on the surface of cells or tissues of interest. Such nanotargeted therapy might transform AVM treatment with new embolic agents.
乙烯-乙烯醇共聚物，Onyx®（ev3，Inc.，明尼苏达州，美国），是一种用于治疗动静脉畸形（AVMs）的栓塞剂，于 2005 年获得美国 FDA 批准。与以前的栓塞剂如 N-丁基-2-氰基丙烯酸酯相比，使用 Onyx 可提高治愈率。与以前的栓塞剂相比，Onyx 具有多个优势。例如，Onyx 是一种共聚物，不会粘在导管上，但由于其溶剂二甲基亚砜的扩散，它会缓慢固化。这篇综述重点介绍了不同神经介入医生的经验所获得的不同结果，重点是治愈的目的。根据治愈率、发病率和死亡率对所提出的研究进行了比较。提出了使用纳米靶向治疗的未来 AVM 破裂治疗方案的想法，该治疗方案由在感兴趣的细胞或组织表面高度表达的特定标记物引导。这种纳米靶向治疗可能会改变新栓塞剂的 AVM 治疗。
